secwatch.observer — SEC 8-K summary
======================================

Issuer:     Day One Biopharmaceuticals, Inc. (—)
CIK:        0001845337
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262560
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Day One Biopharma R&D Head Samuel Blackman retiring; to advise
--------------------------------------------------------------

- Samuel Blackman, co-founder and Head of R&D, will retire effective end of 2024.
- Blackman served as Head of R&D since May 2023; previously Chief Medical Officer since founding.
- He will remain as a strategic advisor and consultant during search for successor.
- Company has initiated search for new Head of Research & Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845337/000119312524262560/0001193125-24-262560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845337/000119312524262560/d856064d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer